Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) – Research analysts at Jefferies Group reduced their FY2017 earnings per share (EPS) estimates for Valeant Pharmaceuticals International in a report released on Wednesday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings per share of $3.45 for the year, down from their prior estimate of $3.76. Jefferies Group currently has a “Buy” rating and a $18.00 price target on the stock.

A number of other equities analysts have also recently commented on VRX. BMO Capital Markets reissued a “hold” rating and set a $15.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, July 27th. Zacks Investment Research upgraded Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 27th. Deutsche Bank AG set a $19.00 price objective on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Monday, July 17th. J P Morgan Chase & Co set a $10.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, July 17th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price target on shares of Valeant Pharmaceuticals International in a research report on Friday, June 30th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $17.31.

TRADEMARK VIOLATION NOTICE: “Equities Analysts Set Expectations for Valeant Pharmaceuticals International, Inc.’s FY2017 Earnings (VRX)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2017/08/12/equities-analysts-set-expectations-for-valeant-pharmaceuticals-international-inc-s-fy2017-earnings-vrx.html.

Shares of Valeant Pharmaceuticals International (VRX) opened at 13.89 on Thursday. The company’s market capitalization is $4.83 billion. The firm has a 50-day moving average price of $16.57 and a 200-day moving average price of $13.38. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The business had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. Valeant Pharmaceuticals International’s revenue was down 7.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share.

Several large investors have recently modified their holdings of VRX. Cambridge Advisors Inc. increased its stake in shares of Valeant Pharmaceuticals International by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock worth $140,000 after buying an additional 75 shares during the last quarter. Armstrong Henry H Associates Inc. increased its position in shares of Valeant Pharmaceuticals International by 0.3% in the second quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock valued at $1,622,000 after buying an additional 295 shares in the last quarter. World Asset Management Inc increased its position in shares of Valeant Pharmaceuticals International by 1.5% in the first quarter. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company’s stock valued at $237,000 after buying an additional 328 shares in the last quarter. Eaton Vance Management increased its position in shares of Valeant Pharmaceuticals International by 1.2% in the second quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock valued at $752,000 after buying an additional 500 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of Valeant Pharmaceuticals International by 0.4% in the second quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock valued at $2,220,000 after buying an additional 509 shares in the last quarter. 51.14% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Earnings History and Estimates for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.